US House Votes to Give FDA More Power Over Accelerated Approvals

On Wednesday, the U.S. House of Representatives voted on a bill that would give the U.S. Food and Drug Administration more power to ensure biopharma companies run large follow-up trials to confirm accelerated approvals. The bill must be passed by September, or the FDA will face funding gaps.